ClinicalTrials.Veeva

Menu

The Second COVID-19 Wave: Collateral Impact on Patients of Liver Disease

I

Institute of Liver and Biliary Sciences, India

Status

Completed

Conditions

Liver Diseases

Treatments

Other: This is an observational study

Study type

Observational

Funder types

Other

Identifiers

NCT05167305
ILBS-COVID-07

Details and patient eligibility

About

Hospital record of the patients of liver disease admitted from April-May 2021 and April-May 2019 will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and the subsequent 30 d and 90 day readmission rate.

Monitoring and assessment: Hospital records of all patients of liver disease needing admission during the April-May 2019 and 2021, but without active COVID-19 infection, will be reviewed. Patients will be analyzed and compared for the demographic characteristics, severity of liver disease at time of admission and outcome in form of survival or mortality, liver transplantation rates in the two time periods and 30 d and 90 d readmission rate.

Enrollment

1,316 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients of liver disease requiring hospital admission

Exclusion criteria

  1. Active COVID-19 infection at time of admission or acquiring during hospital stay.

Trial design

1,316 participants in 2 patient groups

liver disease without COVID-19 infection-April-May 2019
Treatment:
Other: This is an observational study
liver disease without COVID-19 infection -April- May 2021
Treatment:
Other: This is an observational study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems